Multiple drug resistance

Medicinal Research Reviews

Volumn 19, Issue 6, 1999, Pages 477-496

  Mitscher, Lester A ^a,b,c   Pillai, Segaran P ^a   Gentry, Elmer J ^a   Shankel, Delbert M ^a,d  

^a UNIVERSITY OF KANSAS   (United States)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Multiple drug resistance

Indexed keywords

8 (3 AMINO 1 PYRROLIDINYL) 1 CYCLOPROPYL 7 FLUORO 9 METHYL 4 OXO 3 QUINOLIZINECARBOXYLIC ACID; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIPROTOZOAL AGENT; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; DOXYCYCLINE; HMR 3004; IMIPENEM; KANAMYCIN; MACROLIDE; MEROPENEM; METICILLIN; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TETRACYCLINE; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG;

ANTIBIOTIC THERAPY; BACTERIAL CELL WALL; BACTERIAL MUTATION; DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; DRUG UPTAKE; ENZYME BINDING; GENE EXPRESSION; GENETIC RESISTANCE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MULTIPLE; HUMANS;

EID: 0032737297     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1128(199911)19:6<477::AID-MED2>3.0.CO;2-W     Document Type: Review

References (33)

1. Travis T. Reviving the antibiotic miracle. Science 1994;264:360-362.
2. Poyart C, Pierre C, Quesne G, Pro B, Yrieu-Cuot P. Emergence of Vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob Agts Chemother 1997;41:24-29.
3. Levy SB. The challenge of antibiotic resistance. Sci Am 1998;1998:46-53.
4. Domagala JM, Sanchez JP. New approaches and agents to overcome bacterial resistance. Ann Rep Med Chem 1997;32:111-120.
5. Cohen ML. Epidemiology of drug resistance: implications for a post antimicrobial era. Science 1992; 257:1050-1054.
6. Watanabe T. Infectious heredity of multiple drug resistance in bacteria. Bacteriol Rev 1963;27:27-87.
7. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica Biophys Acta 1976;455:152-162.
8. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993;90:7915-7922.
9. Witte W. Medical consequences of antibiotic use in agriculture. Science 1998;279:996-997.
10. Ferber D. New hunt for the roots of resistance. Science 1998;280:27.
11. Morell V. Antibiotic resistance: road of no return. Science 1997;278:575-576.
12. Nikado H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 1994;264:382-388.
13. Sum PE, Lee VJ, Testa RT, Hlavka JJ, Ellestad GA, Bloom JD, Glutzman Y, Tally FP. Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem 1994;37:184-188.
14. Nelson ML, Park BH, Andrews JS, Georgian VA, Thomas RC, Levy SB. Inhibition of the tetracycline efflux antiport protein by 13-thiosubstituted 5-hydroxy-6-deoxytetracyclines. J Med Chem 1993;36:370-377.
15. Davis BD. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 1987;51:341-350.
16. Chang MH, Choi KI, Cha JH, Pae AN, Cho YS, Kang HY, Koh HY. Studies on new catechol containing cephalosporins. 2. Synthesis and structure-activity relationships of cephalosporins having a catechol moiety at the C-7 position. J Antibiot 1995;48:1375-1377.
17. Palzkill T. β-Lactamases are changing their activity spectrums. ASM News 1998;64:90-95.
18. Livermore DM. Bacterial resistance to carbapenems in Antimicrobial resistance: a crisis in health care. Jungkind DL, Mortensen JE, Fraimow HS, Calandra GB, editors. New York: Plenum; 1995. p 32-37.
19. Waters B, Davies J. Amino acid variation in the gyrA subunit of bacteria potentially associated with natural resistance to fluoroquinolone antibiotics. Antimicrob Agents Chemother 1997;41:2766-2769.
20. Li Q, Mitscher LA, Shen LL. The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors. Med Res Rev 1999; to appear.
21. Molla A, Kohlbrenner WE. Resistance to antiretroviral drug therapy. Ann Rep Med Chem 1997;32:131-140.
22. Agouridas C, Denis A, Auger JM, Benedetti Y, Bonnefoy A, Bretin F, Chantot JF, Dussarat A, Fromentin C, D'Ambrieres SG, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessot N. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. J Med Chem 1998;41:4080-4100.
23. Rotun SS, McMath V, Schoonmaker DJ, Maupin PS, Tenover FC, Hill BC, Ackman DM. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerging Infect Dis 1999;5:147-149.
24. Holzman D. Despite insights, antibiotic resistance raises serious concerns. ASM News 1998;64:317-318.
25. Genin MJ, Hutchinson DK, Allwine DA, Hester JB, Emmert DE, Garmon SA, Ford CW, Zurenko GE, Hamel JC, Schaadt RD, Stapert D, Yagi BH, Friis JM, Shobe EM, Adams WJ. Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious Gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis. J Med Chem 1998;41:5144-5147.
26. Wang ZY, Cheng SJ, Zhou ZC, Athar M, Khan WA, Bickers DR, Mukhtar H. Antimutagenic activity of green tea polyphenols. Mutation Res 1989;223:273-285.
27. McMurry LM, Oethinger M, Levy SB. Triclosan targets lipid synthesis. Nature 1998;394:531-532.
28. Molla A, Kohlbrenner WE. Resistance to antiretroviral drug therapy. Ann Rep Med Chem 1997;32:131-140.
29. Georgopapadakou NH. Antifungals: mechanism of action and resistance, established and novel drugs. Curr Op Microbiol 1998;1:547-557.
30. Lum BL, Gosland MP, Kaubisch S, Sikic BI. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacother 1993;13:88-109.
31. Chicarelli-Robinson MI, Gibbons S, McNicholas C, Robinson N, Moore M, Fauth U, Wrigley SK. Plants and microbes as complementary sources of chemical diversity for drug discovery. In: Wrigley S, Hayes M, Thomas R, Chrystal E, editors. Phytochemical diversity: A source of new industrial products. Cambridge: Roy Soc Chem; 1997. p 30-40.
32. Norman BH. Inhibitors of MRP1-mediated multidrug resistance. Drug Fut 1999; to appear.
33. Gekeler V, Ise W, Sanders KH, Ulrich W, Beck J. The leukotriene LTD-4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Comm 1995;208:345-352.